Dual controlled release, in situ gelling periodontal sol of metronidazole benzoate and serratiopeptidase: statistical optimization and mechanistic evaluation.
In situ gelling syringeable periodontal sol capable of dual controlled delivery of metronidazole benzoate and serratiopeptidase was designed based on 2(3) factorial design with drug, poloxamer 407 and aerosil as independent variables and sol gel transition characteristics, %CDR(48h) and palatability as responses. The sols had agreeable taste, were mucoadhesive, syringeable and inverted into gels at periodontal cavity temperature. F8 with optimal drug release was identified as the best formulation. The dispersion characteristics of poloxamer significantly affected the pharmacotechnical properties of the in situ gelling systems. Extra design checkpoint generated using Design Expert software 8.02 (Stat-Ease, USA) validated the experimental design. Thus a thermoreversible, in situ gelling and syringeable periodontal sol with acceptable taste characteristics that offered controlled release of metronidazole benzoate and serratiopeptidase was developed for application into the periodontal pocket. The developed optimized sol was satisfactory in terms of taste, syringeability, palatability and incorporation of serratiopeptidase as anti-inflammatory agent, has the potential of developing a therapeutically efficacious system for treatment of periodontal inflammatory anaerobic infections.
Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, India.
Neeraj
N
Kumari
Kamla
K
Pathak
D000268:Adhesiveness; D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000737:chemistry; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000737:chemistry; D001565:Benzoates / Q000008:administration & dosage* / Q000737:chemistry; D002152:Calorimetry, Differential Scanning; D003692:Delayed-Action Preparations; D004355:Drug Stability; D005260:Female; D005782:Gels; D006041:Goats; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage* / Q000737:chemistry; D009061:Mouth Mucosa / Q000737:chemistry; D010447:Peptide Hydrolases / Q000008:administration & dosage* / Q000737:chemistry; D010514:Periodontal Pocket; D011355:Prodrugs / Q000008:administration & dosage* / Q000737:chemistry; D014783:Viscosity
D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001565:Benzoates; D003692:Delayed-Action Preparations; D005782:Gels; D011355:Prodrugs; D008795:Metronidazole; D010447:Peptide Hydrolases; C022640:serratiopeptidase